Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | P551_W557delinsL |
Impact List | indel |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT P551_W557delinsL results in the deletion of seven amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 551 to 557, combined with the insertion of a leucine (L) in the same site (PMID: 16226710). P551_W557delinsL has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT P551_W557delinsL KIT mutant KIT exon11 KIT exon 11 del KIT P551_W557delinsL |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727419_54727439delinsCTT |
cDNA | c.1651_1671delinsCTT |
Protein | p.P551_W557delinsL |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017008178 | chr4:g.54727419_54727439delinsCTT | c.1651_1671delinsCTT | p.P551_W557delinsL | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727419_54727439delinsCTT | c.1651_1671delinsCTT | p.P551_W557delinsL | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727419_54727439delinsCTT | c.1651_1671delinsCTT | p.P551_W557delinsL | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727419_54727439delinsCTT | c.1651_1671delinsCTT | p.P551_W557delinsL | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727419_54727439delinsCTT | c.1651_1671delinsCTT | p.P551_W557delinsL | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727419_54727439delinsCTT | c.1651_1671delinsCTT | p.P551_W557delinsL | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT P551_W557delinsL | gastrointestinal stromal tumor | predicted - sensitive | Ponatinib | Case Reports/Case Series | Actionable | In a clinical study, a GIST patient harboring KIT P551_W557delinsL, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity to Iclusig (ponatinib) treatment, which resulted in tumor regression and stable disease (PMID: 25239608). | 25239608 |